Bruno David
Lourenço Paiva
Investigador en el periodo 2011-2015
Universidad de Navarra
Pamplona, EspañaPublicaciones en colaboración con investigadores/as de Universidad de Navarra (22)
2023
-
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia
Blood Advances, Vol. 7, Núm. 1, pp. 167-173
-
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia
British Journal of Haematology
2022
-
Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study
European Journal of Cancer, Vol. 174, pp. 243-250
-
Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma
Blood Advances, Vol. 6, Núm. 11, pp. 3234-3239
-
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 9, pp. e844-e852
2021
-
Measurable residual disease in elderly acute myeloid leukemia: Results from the PETHEMA-FLUGAZA phase 3 clinical trial
Blood Advances, Vol. 5, Núm. 3, pp. 760-770
-
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
Blood Cancer Journal, Vol. 11, Núm. 12
-
Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma
Cancers, Vol. 13, Núm. 19
-
Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?
Blood, Vol. 138, Núm. 19, pp. 1901-1905
2018
-
Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia
Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73
2016
-
Assessment of minimal residual disease in myeloma and the need for a consensus approach
Cytometry Part B - Clinical Cytometry, Vol. 90, Núm. 1, pp. 21-25
-
Combination of Intra-Articular and Intraosseous Injections of Platelet Rich Plasma for Severe Knee Osteoarthritis: A Pilot Study
BioMed Research International, Vol. 2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
-
Modulation of synovial fluid-derived mesenchymal stem cells by intra-articular and intraosseous platelet rich plasma administration
Stem Cells International, Vol. 2016
-
Use of human pharyngeal and palatine tonsils as a reservoir for the analysis of B-cell ontogeny in 10 paired samples
Clinical Otolaryngology, Vol. 41, Núm. 5, pp. 606-611
-
Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases
Cytometry Part B - Clinical Cytometry, Vol. 90, Núm. 1, pp. 91-100
2015
-
PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma
Leukemia
-
Whole-genome fingerprint of the DNA methylome during human B cell differentiation
Nature Genetics, Vol. 47, Núm. 7, pp. 746-756
2013
-
A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control
Leukemia, Vol. 27, Núm. 10, pp. 2056-2061
-
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma
New England Journal of Medicine, Vol. 369, Núm. 5, pp. 438-447